Xeris Biopharma Swings to Q4 Net Income, Revenue Beats Estimates on Strong Product Demand
XERS sits 75% above its 52-week low of $3.59 on elevated volume (2.9× avg).
Summary
Xeris Biopharma reported strong Q4 results, with product revenue of $83.43 million surpassing analyst estimates of $82.34 million. Crucially, the company swung to a net income of $11.1 million for the quarter, a significant improvement from a net loss in the prior year. This positive performance was driven by robust patient demand for key products, including a 100% increase in Recorlev net revenue. The company also provided 2026 revenue guidance of $375 million to $390 million. This material beat and return to profitability, following recent patent litigation news, signals strong operational momentum and will likely be viewed positively by the market. Investors will monitor the company's ability to execute on its 2026 guidance amidst rising R&D and SG&A expenses.
At the time of this announcement, XERS was trading at $6.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $3.59 to $10.08. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.